Ratings for Albemarle ALB were provided by 17 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 6 | 7 | 1 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 2 | 1 | 1 | 0 | 0 |
2M Ago | 1 | 1 | 2 | 1 | 0 |
3M Ago | 0 | 4 | 3 | 0 | 0 |
Analysts have set 12-month price targets for Albemarle, revealing an average target of $140.12, a high estimate of $188.00, and a low estimate of $81.00. This current average represents a 1.54% decrease from the previous average price target of $142.31.
Deciphering Analyst Ratings: An In-Depth Analysis
The perception of Albemarle by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
John Roberts | Mizuho | Raises | Neutral | $128.00 | $112.00 |
Michael Sison | Wells Fargo | Raises | Overweight | $145.00 | $135.00 |
Andres Castanos Mollor | Berenberg | Raises | Buy | $160.00 | $130.00 |
Patrick Cunningham | Citigroup | Raises | Neutral | $135.00 | $125.00 |
Matthew DeYoe | B of A Securities | Raises | Buy | $156.00 | $137.00 |
Christopher Kapsch | Loop Capital | Lowers | Buy | $162.00 | $168.00 |
Vincent Andrews | Morgan Stanley | Lowers | Underweight | $81.00 | $90.00 |
Kevin McCarthy | Vertical Research | Announces | Hold | $145.00 | - |
John Roberts | Mizuho | Lowers | Neutral | $112.00 | $115.00 |
Aleksey Yefremov | Keybanc | Lowers | Overweight | $159.00 | $178.00 |
John Roberts | Mizuho | Raises | Neutral | $115.00 | $105.00 |
Michael Sison | Wells Fargo | Lowers | Overweight | $135.00 | $140.00 |
Arun Viswanathan | RBC Capital | Lowers | Outperform | $138.00 | $140.00 |
Colin Rusch | Oppenheimer | Lowers | Outperform | $188.00 | $191.00 |
Aleksey Yefremov | Keybanc | Lowers | Overweight | $178.00 | $199.00 |
Joshua Spector | UBS | Lowers | Neutral | $125.00 | $137.00 |
Patrick Cunningham | Citigroup | Lowers | Neutral | $120.00 | $175.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Albemarle. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Albemarle compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Albemarle's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of Albemarle's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Albemarle analyst ratings.
Get to Know Albemarle Better
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the U.S. and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the U.S., Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.
A Deep Dive into Albemarle's Financials
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Albemarle's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -10.1%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Albemarle's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -26.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Albemarle's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -6.4%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Albemarle's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Albemarle's debt-to-equity ratio is below the industry average. With a ratio of 0.45, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.